Unknown

Dataset Information

0

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.


ABSTRACT:

Importance

The US Food and Drug Administration (FDA) grants accelerated approval according to surrogate measures of numerous drug indications for serious or life-threatening illnesses such as infectious diseases and cancer. Investigators, including the FDA, have evaluated the program's regulatory and clinical consequences in oncology, but evaluation of nononcology drugs is lacking.

Objective

To evaluate the accelerated approval program for nononcology drug indications over a period of 26 years.

Design, setting, and participants

This retrospective cohort study used publicly available data on FDA nononcology drug indications granted accelerated approval from June 1992 through May 2018, with preapproval and confirmatory trials for approved drugs. Data were analyzed from February to April 2022.

Main outcomes and measures

The study estimated the median time from accelerated approval to occurrence of regulatory outcomes such as regular approval conversion, postapproval boxed warning label changes, confirmatory trial completion, and confirmatory trial results publication.

Results

The FDA granted accelerated approval of 48 drugs for 57 nononcology indications, including 23 (40%) HIV treatments, supported by 93 preapproval trials. Forty-three indications (75%) were converted to regular approval at a median time of 53.1 (95% CI, 38.7 to 70.2) months from accelerated approval. There were postapproval label modifications on boxed warnings in 27 indications (47%) with a median time of 248.6 (95% CI, 51.8 to not estimable) months from accelerated approval. Of the 86 required confirmatory trials, 17 (20%) had not fulfilled the postapproval requirements. The median time to confirmatory trial completion was 39.4 (95% CI, 30.7 to 47.9) months. Nine trials (10%) failed to verify clinical efficacy, but only 1 of 8 indications assessed (2%) was withdrawn owing to the failed confirmatory trial, which was 136 months after approval. Results were published in 56 completed confirmatory trials (65%), with the median time being 52.5 (95% CI, 35.6 to 82.2) months from accelerated approval to publication.

Conclusions and relevance

Although the program expedited the approval of nononcology drug indications by a median (IQR) of 53.1 (26.8-133.2) months, safety-related label modifications were often added in boxed warnings after approval, and clinical efficacy was sometimes not confirmed. The study findings and long follow-up period suggest that comprehensive evaluation of such drugs may take more than a decade.

SUBMITTER: Omae K 

PROVIDER: S-EPMC9463606 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018.

Omae Kenji K   Onishi Akira A   Sahker Ethan E   Furukawa Toshi A TA  

JAMA network open 20220901 9


<h4>Importance</h4>The US Food and Drug Administration (FDA) grants accelerated approval according to surrogate measures of numerous drug indications for serious or life-threatening illnesses such as infectious diseases and cancer. Investigators, including the FDA, have evaluated the program's regulatory and clinical consequences in oncology, but evaluation of nononcology drugs is lacking.<h4>Objective</h4>To evaluate the accelerated approval program for nononcology drug indications over a perio  ...[more]

Similar Datasets

| S-EPMC8727037 | biostudies-literature
| S-EPMC7900925 | biostudies-literature
| S-EPMC8220494 | biostudies-literature
| S-EPMC9926353 | biostudies-literature
| S-EPMC5817559 | biostudies-literature
| S-EPMC7656288 | biostudies-literature
| S-EPMC3556246 | biostudies-literature